Table of Contents Table of Contents
Previous Page  9 / 31 Next Page
Information
Show Menu
Previous Page 9 / 31 Next Page
Page Background

Heinemann V, et al. Ann Oncol 2015.

RR is the relative risk, EGFRI + CTx/bevacizumab + CTx (%).

Weight is relative weight (%) from the fixed effect model.

Heterogeneity: Chi

2

= 2.81, df = 2, (P = 0.25), I

2

= 29%, Tau

2

= 0

(n = 526)

(n = 342)

(n = 169)

0.78

(0.68−0.90)

0.91

(0.77−1.07)

0.95

(0.75−1.21)

0.85

(0.77−0.94)

0.86

(0.76−0.97)

−0.243

−0.094

−0.050

0.0839

0.1206

48.5

34.7

16.8

100

0.0710

CALGB

FIRE-3

PEAK

Total

Total

(fixed)

(random)

RR (95% CI)

logRR

logSE

Weight

0.1

1

10

WT

RAS

Favours anti-EGFR + CTx

Favours bevacizumab + CTx

Response Rate